Literature DB >> 12409417

Rapid identification and differentiation of Candida albicans and Candida dubliniensis by capillary-based amplification and fluorescent probe hybridization.

Rangaraj Selvarangan1, Ajit P Limaye, Brad T Cookson.   

Abstract

We developed a rapid genotypic assay to differentiate the germ tube-positive yeasts Candida albicans and Candida dubliniensis. Fluorescently labeled nucleic acid probe binding and subsequent denaturation from the target site in the PCR amplicons produced characteristic peak melting temperatures (T(m)) that identified each species. Peak T(m)s of C. albicans (n = 69) and C. dubliniensis (n = 28) isolates produced in the presence of their respective probes were 61.04 +/- 0.64 degrees C and 60.52 +/- 1.01 degrees C (averages +/- standard deviations). No signal was generated when the C. albicans or C. dubliniensis probes were tested against DNA from their counterparts. Both probes reacted with Candida tropicalis DNA, but the T(m) was 51.85 +/- 0.05 degrees C with the C. albicans probe and 51.92 +/- 0.10 degrees C with the C. dubliniensis probe, differentiating C. tropicalis DNA from C. albicans and C. dubliniensis. A novel hybrid probe was designed to identify both species in a single reaction based on a 4 degrees C difference in peak T(m)s. Our assay is rapid (</=2 h) and allows reliable detection and differentiation of the two germ tube-positive Candida spp.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409417      PMCID: PMC139684          DOI: 10.1128/JCM.40.11.4308-4312.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel.

Authors:  I Polacheck; J Strahilevitz; D Sullivan; S Donnelly; I F Salkin; D C Coleman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Molecular characterization by PCR-fingerprinting of Candida dubliniensis strains isolated from two HIV-positive patients in Spain.

Authors:  T M Diaz-Guerra; E Mellado; M Cuenca Estrella; F Laguna; J L Rodriguez-Tudela
Journal:  Diagn Microbiol Infect Dis       Date:  1999-10       Impact factor: 2.803

3.  Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States.

Authors:  T F Meiller; M A Jabra-Rizk; A a Baqui; J I Kelley; V I Meeks; W G Merz; W A Falkler
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-11

4.  Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems.

Authors:  A C Gales; M A Pfaller; A K Houston; S Joly; D J Sullivan; D C Coleman; D R Soll
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

5.  Rapid identification of Candida dubliniensis with commercial yeast identification systems.

Authors:  D H Pincus; D C Coleman; W R Pruitt; A A Padhye; I F Salkin; M Geimer; A Bassel; D J Sullivan; M Clarke; V Hearn
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 6.  Candida dubliniensis: an emerging opportunistic pathogen.

Authors:  D Sullivan; D Coleman
Journal:  Curr Top Med Mycol       Date:  1997-12

7.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

8.  Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea.

Authors:  M J McCullough; K V Clemons; D A Stevens
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

9.  Candida dubliniensis fungemia: the first four cases in North America.

Authors:  M E Brandt; L H Harrison; M Pass; A N Sofair; S Huie; R K Li; C J Morrison; D W Warnock; R A Hajjeh
Journal:  Emerg Infect Dis       Date:  2000 Jan-Feb       Impact factor: 6.883

10.  Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis.

Authors:  G P Moran; D Sanglard; S M Donnelly; D B Shanley; D J Sullivan; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more
  6 in total

1.  Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization.

Authors:  Joao P Frade; David W Warnock; Beth A Arthington-Skaggs
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

2.  Multilocus DNA sequence comparisons rapidly identify pathogenic molds.

Authors:  Jennifer L Rakeman; Uyen Bui; Karen Lafe; Yi-Ching Chen; Rhonda J Honeycutt; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Rapid identification of commonly encountered Candida species directly from blood culture bottles.

Authors:  Rangaraj Selvarangan; Uyen Bui; Ajit P Limaye; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

4.  Rapid identification of pathogenic yeast isolates by real-time PCR and two-dimensional melting-point analysis.

Authors:  A Bergman; V Fernandez; K O Holmström; B E B Claesson; H Enroth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

5.  An interlaboratory comparison of ITS2-PCR for the identification of yeasts, using the ABI Prism 310 and CEQ8000 capillary electrophoresis systems.

Authors:  Thierry De Baere; Anne Van Keerberghen; Peter Van Hauwe; Hans De Beenhouwer; An Boel; Gerda Verschraegen; Geert Claeys; Mario Vaneechoutte
Journal:  BMC Microbiol       Date:  2005-03-18       Impact factor: 3.605

6.  Validation of a simplex PCR assay enabling reliable identification of clinically relevant Candida species.

Authors:  Gabor Fidler; Eva Leiter; Sandor Kocsube; Sandor Biro; Melinda Paholcsek
Journal:  BMC Infect Dis       Date:  2018-08-13       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.